Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients

Bookmark and Share
Published: 7 Dec 2019
Views: 890
Prof Stephen Schuster - University of Pennsylvania, Philadelphia, USA

Prof Stephen Schuster speaks to ecancer at the 2019 ASH meeting in Orlando about the use of mosunetuzumab in patients with non-Hodgkin lymphoma.

He describes the design of this study, along with the results achieved and toxicities observed with the action of this dual-targeting antibody.

Prof Schuster elaborates on this unmet need for patients who do not respond to CAR T-cell therapy.

He concludes by discussing the future use of this drug which is easily accessible due to its off-the-shelf availability.

Watch the press conference here

Read more about the study here